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Background 
Hepa%%s	  C	  is	  a	  viral	  infec%ous	  disease	  that	  is	  a	  major	  cause	  of	  liver	  disease	  around	  the	  
world.	  By	  the	  1970s,	  it	  was	  recognized	  that	  many	  hepa%%s	  cases	  were	  not	  due	  to	  the	  
known	  hepa%%s	  A	  or	  hepa%%s	  B	  viruses.	  It	  was	  not	  un%l	  1989	  when	  the	  virus,	  then	  
known	  as	  non-­‐A,	  non-­‐B	  hepa%%s,	  was	  iden%ﬁed	  as	  a	  new	  dis%nct	  virus,	  hepa%%s	  C.	  The	  
virus	  has	  seven	  major	  genotypes,	  with	  genotype	  1	  causing	  about	  75%	  of	  cases	  in	  the	  
United	  States.	  By	  1990,	  a	  screening	  test	  for	  the	  virus	  was	  developed,	  and	  within	  a	  year,	  
the	  ﬁrst	  treatment	  for	  the	  virus	  was	  approved.1	  
Research	  through	  the	  1990s	  and	  into	  the	  early	  2000s	  improved	  treatment	  op%ons.	  
Before	  2011,	  the	  standard	  of	  care	  treatment	  for	  hepa%%s	  C	  consisted	  of	  pegylated	  
interferon	  and	  ribavirin,	  which	  successfully	  cured	  between	  45%	  and	  80%	  of	  individuals,	  
depending	  on	  the	  speciﬁc	  genotype	  of	  HCV.	  In	  recent	  years,	  new	  treatments	  consis%ng	  
of	  a	  combina%on	  of	  ledpiasivir,	  sofosbuvir,	  ribavirin,	  and	  pegylated	  interferon	  have	  
improved	  the	  cure	  rate	  to	  up	  to	  99%	  in	  some	  genotypes.2	  	  These	  drugs	  work	  without	  
the	  many	  severe	  side	  eﬀects	  of	  older	  classes	  of	  drugs,	  which	  had	  a	  rela%vely	  high	  risk	  of	  
causing	  life	  threatening	  hemoly%c	  anemia.3	  However,	  the	  cost	  of	  these	  new	  treatments	  
can	  approach	  $100,000	  for	  a	  twelve-­‐week	  therapy,	  making	  the	  cost	  of	  treatment	  
prohibi%vely	  expensive	  for	  many	  Americans.	  4	  
Epidemiology and Transmission in the  
Philadelphia Homeless Population 
Hepa%%s	  C	  is	  common,	  with	  approximately	  200	  million	  people	  	  
livingwith	  chronic	  hepa%%s	  C	  (3%	  of	  the	  world’s	  popula%on).	  	  
Over	  recent	  decades,	  an	  increase	  in	  intravenous	  drug	  use	  has	  	  
led	  to	  increased	  rates	  of	  exposure	  to	  the	  virus.	  In	  Philadelphia,	  	  
rates	  are	  higher	  than	  the	  na%onal	  average	  with	  seroprevalence	  	  
es%mates	  ranging	  from	  30,000-­‐45,000	  (2-­‐3%),	  with	  only	  10-­‐15%	  	  
of	  those	  currently	  receiving	  treatment.	  An	  es%mated	  4,000	  	  
Philadelphians	  are	  diagnosed	  with	  HCV	  each	  year.	  When	  broken	  down	  by	  race,	  
approximately	  45%	  of	  cases	  are	  found	  in	  non-­‐Hispanic	  African	  Americans,	  30%	  in	  non-­‐
Hispanic	  Caucasians,	  and	  15%	  in	  Hispanics.5	  
	  
Hepa%%s	  C	  prevalence	  is	  high	  among	  homeless	  individuals.	  	  
Recent	  studies	  in	  the	  United	  States	  of	  the	  prevalence	  of	  HCV	  	  
infec%ons	  inthe	  homeless	  have	  shown	  an	  es%mated	  prevalence	  	  
ranging	  from	  8%	  to	  35%.	  A	  widely	  reported	  2012	  study	  of	  the	  	  
homelesspopula%on	  in	  Los	  Angeles	  showed	  that	  over	  27%	  of	  homeless	  	  
adults	  in	  downtown	  L.A.	  were	  infected	  with	  HCV.	  As	  expected,	  infec%on	  rates	  were	  
higher	  amongst	  intravenous	  drug	  users,	  as	  well	  as	  those	  who	  were	  previously	  
incarcerated.6	  While	  there	  have	  been	  no	  published	  studies	  on	  the	  prevalence	  of	  HCV	  in	  
the	  homeless	  popula%on	  of	  Philadelphia,	  it	  is	  likely	  that	  the	  rates	  should	  be	  similar	  to	  
the	  seroprevalence	  in	  other	  major	  ci%es	  in	  the	  United	  States.	  	  
	  
Implementation of a Hepatitis C Screening, Education,  
and Treatment Program at JeffHOPE 
Screening	  
JeﬀHOPE	  clinics	  serve	  as	  student-­‐run	  clinics	  for	  the	  underserved	  and	  	  
homeless	  popula%on	  of	  Philadelphia.	  Prior	  to	  2010,	  the	  only	  test	  	  
available	  for	  HCV	  was	  an	  enzyme	  immunoassay	  and	  recombinant	  immunoblot	  assay	  or	  HCV	  RNA	  
tes%ng,	  which	  were	  accurate	  but	  expensive	  and	  slow.	  In	  recent	  years,	  the	  FDA	  has	  approved	  the	  
OraQuick	  Rapid	  HCV	  test,	  which,	  similar	  to	  the	  test	  currently	  used	  for	  HIV	  tes%ng,	  tests	  for	  HCV	  
an%bodies.	  Also	  similar	  to	  the	  HIV	  test,	  the	  HCV	  instant	  test	  requires	  a	  small	  blood	  sample	  and	  the	  
results	  are	  available	  within	  twenty	  minutes.	  If	  a	  pa%ent	  tests	  posi%ve,	  further	  tes%ng	  is	  needed	  to	  
see	  if	  the	  pa%ent	  is	  currently	  infected	  with	  the	  virus.	  A	  rapid	  test	  for	  HCV	  would	  be	  greatly	  beneﬁcial	  
for	  popula%ons	  in	  shelters,	  as	  they	  would	  be	  able	  to	  get	  their	  results	  quickly,	  and	  on	  the	  same	  day	  
be	  provided	  with	  educa%on	  and	  treatment	  op%ons	  that	  may	  be	  available.	  Recent	  studies	  have	  
shown	  a	  97.8%	  sensi%vity	  and	  100%	  speciﬁcity	  of	  the	  rapid	  HCV	  test.7	  
Educa-on	  
An	  important	  component	  of	  the	  JeﬀHOPE	  clinics	  is	  providing	  pa%ents	  with	  health	  educa%on.	  There	  
may	  be	  many	  misconcep%ons	  about	  the	  transmission,	  symptoms,	  and	  treatment	  opportuni%es	  that	  
should	  be	  addressed	  in	  a	  comprehensive	  tes%ng	  program.	  The	  most	  important	  educa%on	  to	  provide	  
is	  how	  to	  prevent	  the	  spread	  and	  contrac%on	  of	  HCV,	  and	  there	  are	  numerous	  resources	  already	  
available	  from	  the	  CDC	  and	  other	  health	  organiza%ons	  that	  discuss	  the	  risk	  factors	  for	  transmission.	  
Of	  par%cular	  concern	  in	  the	  popula%ons	  seen	  at	  JeﬀHOPE	  clinics	  is	  sharing	  of	  any	  injec%on	  
equipment	  used	  to	  inject	  drugs	  or	  any	  other	  substances.	  Informa%on	  about	  syringe	  exchange	  
programs	  in	  the	  area	  can	  also	  be	  provided	  to	  injec%on	  drug	  users,	  to	  help	  minimize	  their	  risk	  of	  
infec%on.	  Pa%ents	  should	  also	  be	  encouraged	  to	  come	  back	  for	  retes%ng,	  most	  likely	  every	  four	  to	  
six	  months,	  par%cularly	  if	  they	  are	  at	  a	  high	  risk	  for	  infec%on,	  or	  have	  recently	  engaged	  in	  ac%vity	  
that	  they	  believe	  puts	  them	  at	  a	  higher	  risk	  of	  infec%on.	  Since	  hepa%%s	  C	  may	  not	  cause	  any	  
symptoms,	  pa%ents	  also	  should	  be	  aware	  that	  even	  if	  they	  are	  feeling	  ﬁne,	  they	  may	  s%ll	  be	  
infected.	  	  
Treatment	  
When	  discussing	  op%ons	  for	  individuals	  who	  test	  posi%ve	  for	  HCV,	  many	  factors	  must	  be	  considered,	  
including	  ease	  of	  treatments,	  cost,	  insurance	  coverage,	  and	  eﬀec%veness	  of	  treatment.	  The	  ﬁeld	  of	  
HCV	  treatment	  has	  changed	  rapidly	  in	  recent	  years,	  with	  many	  treatments	  now	  available	  that	  are	  
more	  eﬀec%ve	  and	  have	  fewer	  side	  eﬀects	  than	  op%ons	  that	  were	  available	  only	  a	  few	  years	  ago.	  
However,	  the	  cost	  of	  these	  newer	  treatment	  op%ons	  may	  make	  it	  diﬃcult	  for	  JeﬀHOPE	  pa%ents	  to	  
receive	  adequate	  treatments.	  Unfortunately,	  Medicaid	  in	  Pennsylvania	  may	  not	  reimburse	  for	  HCV	  
medica%ons,	  including	  sofosbuvir,	  unless	  the	  pa%ent	  already	  has	  severe	  liver	  damage.8	  Many	  
resources	  exist	  in	  Philadelphia	  for	  care	  and	  assistance	  with	  dealing	  with	  	  
hepa%%s	  C,	  including	  community	  health	  centers	  that	  may	  be	  able	  to	  	  
provide	  treatment	  op%ons	  for	  those	  who	  are	  uninsured	  or	  underinsured.	  
The	  Philadelphia	  Department	  	  of	  Public	  Health	  runs	  a	  website,	  Philly	  	  
Hepa++s,	  where	  they	  provide	  a	  list	  of	  op%ons	  that	  are	  available.9	  All	  of	  	  
these	  barriers	  to	  care	  must	  be	  considered	  when	  providing	  tes%ng	  to	  	  
pa%ents,	  as	  just	  tes%ng	  for	  the	  virus	  without	  providing	  treatment	  op%ons	  	  





Hepa%%s	  C	  is	  extremely	  prevalent	  in	  the	  homeless	  popula%on	  of	  
Philadelphia,	  and	  the	  current	  lack	  of	  adequate	  screening	  op%ons	  is	  a	  
major	  public	  health	  issue	  that	  requires	  eﬀort	  and	  ini%a%ve	  to	  solve.	  
Recent	  breakthroughs	  in	  treatment	  op%ons	  have	  made	  hepa%%s	  C	  a	  
curable	  disease,	  which	  lends	  even	  greater	  importance	  to	  this	  ini%a%ve.	  
Implemen%ng	  a	  HCV	  screening	  program	  at	  JeﬀHOPE	  clinics	  is	  a	  
worthwhile	  endeavor	  that	  can	  help	  individuals	  ﬁnd	  out	  if	  they	  are	  
infected	  and	  receive	  guidance	  for	  treatment	  op%ons.	  The	  infrastructure	  
for	  such	  a	  program	  already	  exists	  at	  the	  clinics,	  due	  to	  the	  HIV	  screening	  
program.	  The	  greatest	  foreseeable	  obstacle	  is	  the	  high	  cost	  of	  
treatment,	  but	  there	  are	  organiza%ons	  and	  op%ons	  available	  to	  help	  
with	  paying	  for	  the	  medica%ons.	  Addi%onally,	  the	  Medicaid	  guidelines	  
are	  being	  challenged	  in	  many	  states	  and	  access	  to	  the	  medica%ons	  may	  
be	  increased	  in	  the	  future.	  	  
Ul%mately,	  our	  eventual	  goal	  should	  be	  to	  nearly	  solve	  the	  hepa%%s	  C	  
crisis	  in	  the	  homeless	  popula%on,	  through	  tes%ng,	  treatment,	  and	  
educa%on.	  With	  enough	  eﬀort	  and	  resources,	  this	  can	  become	  a	  
solvable	  public	  health	  issue.	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